| 摘要 |
<p>The invention concerns a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and healthy male subjects without PCa, wherein the individual's body fluid concentration of human glandular kallikrein 2 (hK2) and prostate specific antigen (PSA) have been determined. According to the invention, a combination of hK2 and PSA, wherein PSA means the free PSA, the complexed PSA or the total PSA, is used as marker distinguishing PCa patients from BPH and other non-PCa individuals. Furthermore, the invention relates to a method for differentiating patients with indolent or slowly progressive prostate cancers from patients with aggressively progressive prostate cancers.</p> |
